Advocacy Organization to Work with Health Canada with the Goal to Gain Approval
Hemispherx Biopharma (NYSE MKT:HEB) has announced that on Thursday, August 3, 2017 it participated in a meeting in Toronto, Canada with Canadian advocates for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The meeting was lead by Millions Missing Canada and a Canadian physician representing Canadian patients with ME/CFS, in support of a collaborative effort to advance ME/CFS research and potential treatments in Canada. http://www.millionsmissingcanada.ca/links-and-resources/ This joint effort, which includes Dr. Ian Hyams, a leading physician specializing in ME/CFS management is the next step to bringing Ampligen® to Canadians suffering from the disease.
One
year ago, Ampligen® became the first drug therapy approved in the world
for ME/CFS, receiving government approval from the Republic of
Argentina. Applications for Early Access Programs (EAP) in Europe and
elsewhere are planned in the coming year. In the United States,
Hemispherx has completed a pivotal Phase 3 clinical trial in ME/CFS,
where it is the only late-stage drug in the pipeline for this disease.
The U.S. FDA has advised that potential approval for commercial sale in
the U.S. will require the conduct and review of a follow up confirmatory
clinical trial. Ampligen® is also currently being used in patients with
pancreatic cancer in an EAP in Europe.
Dr. Hyams
is the medical director of the chronic fatigue and pain clinic in West
Vancouver, British Columbia ("BC"), specializing in ME/CFS and
fibromyalgia management as well as the management of similar disorders.
Dr. Hyams is a consultant at the Complex Chronic Diseases Program at BC
Woman's Hospital in Vancouver and is a clinical instructor in the
Department of Family Medicine at the University of British Columbia with
responsibilities in the training of medical students and residents.
Dr.
Hyams, who has treated ME patients with Ampligen® in England and
United States said that, both in his practice and in the Phase 3
clinical trial data, he has "seen significant improvement in ME patients
receiving Ampligen®." Treatment with Ampligen® is by twice weekly
intravenous infusions.
"We are pleased to work
with Millions Missing Canada on this very important issue," said Thomas
K. Equels, CEO and President of Hemispherx. "By working together we hope
to be better able to achieve the goal of providing an effective therapy
for the hundreds of thousands of people who suffer from ME. This unmet
medical need must be addressed. Hemispherx and Millions Missing Canada
will follow the model that Hemispherx used to obtain approval in
Argentina by seeking a Canadian Pharmaceutical Partner who will file for
regulatory approval in Canada."
The plan is to
use the existing Ampligen® new drug application database, to gain
approval of Ampligen® in severely debilitated ME/CFS patients in Canada.
"Canada has the highest ME rates in the world
with 1.9% of the Canadian population suffering from this disease," said
Scott Simpson, a ME patient and advocate and representative of Millions
Missing Canada. Mr. Simpson further stated "For Millions Missing
Canada to collaborate with Hemispherx to bring Ampligen® to Canada
brings real data-driven hope to more than half a million Canadians with
ME where little existed before."
"The time has
come for physicians in Canada to realize that Myalgic Encephalomyelitis
(ME) is a severely disabling disease for many, causing an increase in
patients going on disability. I have personally witnessed as a physician
treating these disorders for the last 25 years the potential for
severely afflicted patients to rebuild quality of life, often resulting
in patients being able to go back to work. It is an honor for me to be
involved in the process of potentially introducing this drug to Canada,
which will hopefully lead to many patients in need receiving this
treatment," said Dr. Hyams.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because rintatolimod is experimental in nature, it is not designated safe and effective by the FDA for general use and is legally available only through clinical trials. For more information about Hemispherx visit www.hemispherx.net.
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because rintatolimod is experimental in nature, it is not designated safe and effective by the FDA for general use and is legally available only through clinical trials. For more information about Hemispherx visit www.hemispherx.net.
No comments:
Post a Comment